Tech Center 1600 • Art Units: 1600 1671 1672
This examiner grants 100% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18035809 | ENGINEERED PROTEIN FOR RAPID, EFFICIENT CAPTURE OF PATHOGEN-SPECIFIC ANTIBODIES | Non-Final OA | Massachusetts Institute of Technology |
| 18549722 | SUBUNIT VACCINES WITH DINUCLEOTIDE-LOADED HYDROGEL ADJUVANT | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18330475 | TETRAVALENT DENGUE INACTIVATED VACCINE | Non-Final OA | ARMY MEDICAL UNIVERSITY |
| 18272115 | VACCINE COMPOSITIONS | Non-Final OA | Oxford University Innovation Limited |
| 18277879 | NOVEL BACTERIOPHAGE HAVING CLOSTRIDIUM PERFRINGENS-SPECIFIC BACTERICIDAL EFFECT AND ANTIBACTERIAL COMPOSITION COMPRISING SAME | Non-Final OA | CJ CheilJedang Corporation |
| 18573410 | Method for Concentrating Virus Sample | Non-Final OA | Kyoto University |
| 18271640 | NANOWIRE-BASED IMMUNOFLUORESCENCE KIT FOR DETECTING SARS CORONAVIRUS 2 ANTIBODY, AND USE THEREOF | Non-Final OA | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY |
| 18448721 | DOSING AND SCHEDULING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES | Non-Final OA | Gilead Sciences, Inc. |
| 18450149 | UBIQUITIN VARIANT WITH HIGH AFFINITY FOR BINDING 53BP1 REDUCES THE AMOUNT OF AAV NEEDED TO ACHIEVE HIGH RATES OF HDR | Non-Final OA | Integrated DNA Technologies, Inc. |
| 18285148 | NANOGEL-COATED VACCINE | Non-Final OA | HanaVax Inc. |
| 18283516 | IMMUNOGENIC COMPOSITIONS | Non-Final OA | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC |
| 18466675 | MICROBIOME IDENTIFICATION AND BACTERIOPHAGE FORMULATIONS | Non-Final OA | Parallel Health, Inc. |
| 18549941 | VACCINE COMPOSITION COMPRISING A LEISHMANIA HOST CELL EXPRESSING AT LEAST ONE PROTEIN OF THE FAMILY CORONAVIRIDAE | Non-Final OA | Vismederi S.R.L. (10%) |
| 18366915 | VACCINES FOR THE TREATMENT AND PREVENTION OF SEASONAL AND EMERGING INFECTIONS | Non-Final OA | Longhorn Vaccines and Diagnostics, LLC |
| 18264408 | ANTIBODIES AGAINST RESPIRATORY SYNCYTIAL VIRUS, HUMAN METAPNEUMOVIRUS AND PNEUMONIA VIRUS OF MICE AND METHODS OF USING THE SAME | Non-Final OA | Humabs BioMed SA |
| 18270917 | FULLY HUMAN BROAD-SPECTRUM NEUTRALIZING ANTIBODY 76E1 AGAINST CORONAVIRUS, AND USE THEREOF | Non-Final OA | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES |
| 18270390 | Method of Obtaining Betulin as an Adjuvant in a Vaccine Against Coronavirus SARS-COV-2 | Non-Final OA | BETUVAKS LIMITED LIABILITY COMPANY |
| 18344693 | CONTROL FOR PROTEIN-BASED ASSAY | Non-Final OA | ZeptoMetrix LLC |
| 18248166 | METHOD FOR DETERMINING WHETHER OR NOT VIRUS-NEUTRALIZING ANTIBODIES ARE PRESENT AND IN VITRO METHOD FOR SCREENING COMPOUNDS FOR THEIR ABILITY TO NEUTRALIZE A VIRUS | Non-Final OA | EXIMMIUM BIOTECHNOLOGIES GMBH |
| 18256484 | METHODS OF PRODUCING ADENOVIRUS | Non-Final OA | ASTRAZENECA UK LIMITED |
| 17794862 | DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF | Non-Final OA | SERUM INSTITUTE OF INDIA PRIVATE LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy